A statement released earlier today by Joh. Berenberg Gossler & Co. KG about Fresenius (ETR:FRE) raises the target price to 77.25EUR
- Updated: September 23, 2016
Having a price of 72.84EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. The last closing price is up 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Fresenius has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade held steady, with 0 shares of FRE changing hands on par with the typical 0
In a report issued 9/23/2016 Joh. Berenberg Gossler & Co. KG bumped up the target of Fresenius (ETR:FRE) to 77.25EUR indicating a possible upside of 0.06%.
On 09/22/2016, Joh. Berenberg Gossler & Co. KG released a statement about Fresenius (ETR:FRE) increased the target price from 0.00EUR to 71.30EUR. At the time, this suggested an upside of 0.00%.
With a total market value of 0 EUR, Fresenius has with a 52 week low of 0.00EUR and a 52 week high of 0.00EUR .
General Information About Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company's operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.